New and emerging treatments of Charcot–Marie–Tooth disease

Bibliography

• Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 1974;6(2):98
   PubMed Web of Science ®Google Scholar
• Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980;17(5):329
   PubMed Web of Science ®Google Scholar
• Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103(2):259
   PubMed Web of Science ®Google Scholar
• Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66(2):219
   PubMed Web of Science ®Google Scholar
• Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993;5(1):31
   PubMed Web of Science ®Google Scholar
• Sivakumar K, Kyriakides T, Puls I, et al. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain 2005;128(Pt 10):2304
   PubMed Web of Science ®Google Scholar
• Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003;72(5):1293
   PubMed Web of Science ®Google Scholar
• Scherer SS. The biology and pathobiology of Schwann cells. Curr Opin Neurol 1997;10(5):386-97
   PubMed Web of Science ®Google Scholar
• Mirsky R, Jessen KR. Schwann cell development, differentiation and myelination. Curr Opin Neurobiol 1996;6(1):89-96
   PubMed Web of Science ®Google Scholar
• Arroyo EJ, Scherer SS. On the molecular architecture of myelinated fibers. Histochem Cell Biol 2000;113(1):1-18
   PubMed Web of Science ®Google Scholar
• Salzer JL. Polarized domains of myelinated axons. Neuron 2003;40(2):297-318
   PubMed Web of Science ®Google Scholar
• Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69(1):22
   PubMed Web of Science ®Google Scholar
• Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012;83(7):706
   PubMed Web of Science ®Google Scholar
• Latour P, Gonnaud PM, Ollagnon E, et al. SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 2006;11(2):148
   PubMed Web of Science ®Google Scholar
• Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010;362(13):1181-91
   PubMed Web of Science ®Google Scholar
• Auer-Grumbach M, Weger M, Fink-Puches R, et al. Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain 2011;134(Pt 6):1839-52
   PubMed Web of Science ®Google Scholar
• Oates EC, Rossor AM, Hafezparast M, et al. Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet 2013;92(6):965
   PubMed Web of Science ®Google Scholar
• Gonzalez M, McLaughlin H, Houlden H, et al. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry 2013;84(11):1247
   PubMed Web of Science ®Google Scholar
• Kennerson ML, Yiu EM, Chuang DT, et al. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum Mol Genet 2013;22(7):1404-16
   PubMed Web of Science ®Google Scholar
• Leipold E, Liebmann L, Korenke GC, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet 2013.45(11):1399-404
   Google Scholar
• Barwick KE, Wright J, Al-Turki S, et al. Defective presynaptic choline transport underlies hereditary motor neuropathy. Am J Hum Genet 2012;91(6):1103
   PubMed Web of Science ®Google Scholar
• Tischfield MA, Baris HN, Wu C, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010;140(1):74-87
   PubMed Web of Science ®Google Scholar
• Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66(2):219-32
   PubMed Web of Science ®Google Scholar
• Berciano J, Gallardo E, Garcia A, et al. CMT1A duplication: refining the minimal adult phenotype. J Peripher Nerv Syst 2008;13(4):310-12
   PubMed Web of Science ®Google Scholar
• Brewer MH, Ma KH, Beecham GW, et al. Haplotype-specific modulation of a SOX10/CREB response element at the Charcot-Marie-Tooth disease type 4C locus SH3TC2. Hum Mol Genet 2014;23(19):5171-87
   PubMed Web of Science ®Google Scholar
• Katona I, Wu X, Feely SM, et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain 2009;132(Pt 7):1734-40
   PubMed Web of Science ®Google Scholar
• Garbay B, Heape AM, Sargueil F, Cassagne C. Myelin synthesis in the peripheral nervous system. Prog Neurobiol 2000;61(3):267-304
   PubMed Web of Science ®Google Scholar
• Jang SW, Lopez-Anido C, MacArthur R, et al. Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol 2012;7(7):1205-13
   PubMed Web of Science ®Google Scholar
• Jones EA, Lopez-Anido C, Srinivasan R, et al. Regulation of the PMP22 gene through an intronic enhancer. J Neurosci 2011;31(11):4242-50
   PubMed Web of Science ®Google Scholar
• Shin YK, Jang SY, Lee HK, et al. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. Glia 2010;58(16):1961-76
   PubMed Web of Science ®Google Scholar
• Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. (Erratum appears in Nat Genet. 2004 Jun;36(6):660. Note: Battologlu E [corrected to Battaloglu E]) Nat Genet 2004;36(5):449-51
   PubMed Web of Science ®Google Scholar
• Rojo M, Legros F, Chateau D, Lombes A. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J Cell Sci 2002;115(Pt 8):1663
   PubMed Web of Science ®Google Scholar
• Chen H, Detmer SA, Ewald AJ, et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003;160(2):189-200
   PubMed Web of Science ®Google Scholar
• Eura Y, Ishihara N, Yokota S, Mihara K. Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J Biochem 2003;134(3):333-44
   PubMed Web of Science ®Google Scholar
• Misko A, Jiang S, Wegorzewska I, et al. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 2010;30(12):4232-40
   PubMed Web of Science ®Google Scholar
• Charcot-Marie-Tooth Association. CMTA Charcot-Marie-Tooth Association-CMT Types 2A and 2E. 2014. Available from: http://www.cmtausa.org/ [cited 18 December 2014]
   Google Scholar
• Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996;4(1):25
   PubMed Web of Science ®Google Scholar
• D’Urso D, Brophy PJ, Staugaitis SM, et al. Protein zero of peripheral nerve myelin: biosynthesis, membrane insertion, and evidence for homotypic interaction. Neuron 1990;4(3):449-60
   PubMed Web of Science ®Google Scholar
• Filbin MT, Walsh FS, Trapp BD, et al. Role of myelin P0 protein as a homophilic adhesion molecule. Nature 1990;344(6269):871-2
   PubMed Web of Science ®Google Scholar
• Shapiro L, Doyle JP, Hensley P, et al. Crystal structure of the extracellular domain from P0, the major structural protein of peripheral nerve myelin. Neuron 1996;17(3):435-49
   PubMed Web of Science ®Google Scholar
• Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127(Pt 2):371
   PubMed Web of Science ®Google Scholar
• Khajavi M, Inoue K, Wiszniewski W, et al. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005;77(5):841-50
   PubMed Web of Science ®Google Scholar
• Grandis M, Vigo T, Passalacqua M, et al. Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Hum Mol Genet 2008;17(13):1877
   PubMed Web of Science ®Google Scholar
• Wrabetz L, D’Antonio M, Pennuto M, et al. Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice. J Neurosci 2006;26(8):2358-68
   PubMed Web of Science ®Google Scholar
• Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013;12(9):703-19
   PubMed Web of Science ®Google Scholar
• Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007;81(3):438
   PubMed Web of Science ®Google Scholar
• Pennuto M, Tinelli E, Malaguti M, et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 2008;57(3):393
   PubMed Web of Science ®Google Scholar
• Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304(5670):600-2
   PubMed Web of Science ®Google Scholar
• Bai Y, Ianokova E, Pu Q, et al. Effect of an R69C mutation in the myelin protein zero gene on myelination and ion channel subtypes. Arch Neurol 2006;63(12):1787-94
   PubMed Web of Science ®Google Scholar
• Saporta MA, Shy BR, Patzko A, et al. MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B. Brain 2012;135(Pt 7):2032
   PubMed Web of Science ®Google Scholar
• Patzko A, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012;135(Pt 12):3551
   PubMed Web of Science ®Google Scholar
• Bejaoui K, Wu C, Scheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001;27(3):261-2
   PubMed Web of Science ®Google Scholar
• Dawkins JL, Hulme DJ, Brahmbhatt SB, et al. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001;27(3):309-12
   PubMed Web of Science ®Google Scholar
• Rotthier A, Auer-Grumbach M, Janssens K, et al. Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet 2010;87(4):513-22
   PubMed Web of Science ®Google Scholar
• Houlden H, King R, Blake J, et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006;129(Pt 2):411
   PubMedGoogle Scholar
• Houlden H, King R, Blake J, et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006;129(Pt 2):411-25
   PubMedGoogle Scholar
• Penno A, Reilly MM, Houlden H, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010;285(15):11178-87
   PubMed Web of Science ®Google Scholar
• Gable K, Gupta SD, Han G, et al. A disease-causing mutation in the active site of serine palmitoyltransferase causes catalytic promiscuity. J Biol Chem 2010;285(30):22846-52
   PubMed Web of Science ®Google Scholar
• Zitomer NC, Mitchell T, Voss KA, et al. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 2009;284(8):4786-95
   PubMed Web of Science ®Google Scholar
• Garofalo K, Penno A, Schmidt BP, et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest 2011;121(12):4735-45
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861-72
   PubMed Web of Science ®Google Scholar
• Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007;2(12):3081-9
   PubMed Web of Science ®Google Scholar
• Lewitzky M, Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol 2007;18(5):467-73
   PubMed Web of Science ®Google Scholar
• Nizzardo M, Simone C, Falcone M, et al. Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell Mol Life Sci 2010;67(22):3837-47
   PubMed Web of Science ®Google Scholar
• Saporta MA, Dang V, Volfson V, et al. Modeling axonal Charcot–Marie–Tooth disease with human IPSC-derived motor neurons. Exp Neurol 2015;263:190-99
   PubMed Web of Science ®Google Scholar
• Martini R, Zielasek J, Toyka KV, et al. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet 1995;11(3):281-6
   PubMed Web of Science ®Google Scholar
• Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996;5(5):563-9
   PubMed Web of Science ®Google Scholar
• Sereda M, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996;16(5):1049-60
   PubMed Web of Science ®Google Scholar
• Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996;16(17):5351-60
   PubMed Web of Science ®Google Scholar
• Desarnaud F, Do Thi AN, Brown AM, et al. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J Neurochem 1998;71(4):1765-8
   PubMed Web of Science ®Google Scholar
• Melcangi RC, Magnaghi V, Cavarretta I, et al. Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J Neurosci Res 1999;56(4):349-57
   PubMed Web of Science ®Google Scholar
• Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9(12):1533
   PubMed Web of Science ®Google Scholar
• Bunge MB, Williams AK, Wood PM, et al. Comparison of nerve cell and nerve cell plus Schwann cell cultures, with particular emphasis on basal lamina and collagen formation. J Cell Biol 1980;84(1):184-202
   PubMed Web of Science ®Google Scholar
• Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10(4):396
   PubMed Web of Science ®Google Scholar
• Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10(4):320-8
   PubMed Web of Science ®Google Scholar
• Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1a: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70(8):981-7
   PubMed Web of Science ®Google Scholar
• Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490(7419):187-91
   PubMed Web of Science ®Google Scholar
• Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. Jama 2006;296(14):1731-2
   PubMed Web of Science ®Google Scholar
• Rare Diseases Clinical Research Network. Inherited Neuropathies Consortium. 2014. Available from: http://www.rarediseasesnetwork.org/INC/ [cited 18 December 2014]
   Google Scholar
• Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70(5):378
   PubMed Web of Science ®Google Scholar
• Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16(3):191
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53(8):1660-4
   PubMed Web of Science ®Google Scholar
• Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16(3):191-8
   PubMed Web of Science ®Google Scholar
• Sadjadi R, Shy M, Reilly M, et al. Psychometric evaluation of Charcot-Marie-Tooth disease (CMT) neuropathy score CMTNS) version 2.0 using Rasch analysis (Abstract). J Peripher Nerv Syst 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012;71(5):642-52
   PubMed Web of Science ®Google Scholar
• Ramchandren S, Shy M, Feldman E, et al. Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease. J Neurol Neurosurg Psychiatry 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Burns J, Ramchandren S, Ryan MM, et al. Determinants of reduced health-related quality of life in pediatric inherited neuropathies. Neurology 2010;75(8):726-31
   PubMed Web of Science ®Google Scholar
• Sinclair CD, Morrow JM, Miranda MA, et al. Skeletal muscle MRI magnetisation transfer ratio reflects clinical severity in peripheral neuropathies. J Neurol Neurosurg Psychiatry 2012;83(1):29
   PubMed Web of Science ®Google Scholar
• Ogilvie CM, Braude PR, Scriven PN. Preimplantation genetic diagnosis – an overview. J Histochem Cytochem 2005;53(3):255-60
   PubMed Web of Science ®Google Scholar
• De Vos A, Sermon K, De Rijcke M, et al. Preimplantation genetic diagnosis for Charcot-Marie-Tooth disease type 1A. Mol Hum Reprod 2003;9(7):429-35
   PubMed Web of Science ®Google Scholar
• De Vos A, Sermon K, Van de Velde H, et al. Pregnancy after preimplantation genetic diagnosis for Charcot-Marie-Tooth disease type 1A. Mol Hum Reprod 1998;4(10):978-84
   PubMed Web of Science ®Google Scholar
• Iacobelli M, Greco E, Rienzi L, et al. Birth of a healthy female after preimplantation genetic diagnosis for Charcot-Marie-Tooth type X. Reprod Biomed Online 2003;7(5):558-62
   PubMedGoogle Scholar
• Altarescu G, Zeevi DA, Zeligson S, et al. Familial haplotyping and embryo analysis for Preimplantation genetic diagnosis (PGD) using DNA microarrays: a proof of principle study. J Assist Reprod Genet 2013;30(12):1595-603
   PubMed Web of Science ®Google Scholar
• Chetlin RD, Gutmann L, Tarnopolsky M, et al. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Arch Phys Med Rehabil 2004;85(8):1217-23
   PubMed Web of Science ®Google Scholar
• Chetlin RD, Gutmann L, Tarnopolsky MA, et al. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle Nerve 2004;30(1):69-76
   PubMed Web of Science ®Google Scholar
• Chetlin RD, Mancinelli CA, Gutmann L. Self-reported follow-up post-intervention adherence to resistance exercise training in Charcot-Marie-Tooth disease patients. Muscle Nerve 2010;42(3):456
   PubMed Web of Science ®Google Scholar
• Kalkman JS, Schillings ML, Zwarts MJ, et al. Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurol Scand 2007;115(4):265-70
   PubMed Web of Science ®Google Scholar
• Carter GT, Abresch RT, Fowler WMJr, et al. Profiles of neuromuscular diseases. Hereditary motor and sensory neuropathy, types I and II. Am J Phys Med Rehabil 1995;74(5 Suppl):S140-9
   PubMed Web of Science ®Google Scholar
• Hogan-Dann CM, Fellmeth WG, McGuire SA, Kiley VA. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984;252(20):2862-3
   PubMed Web of Science ®Google Scholar
• Nakamura T, Hashiguchi A, Suzuki S, et al. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics 2012;13(1):77-82
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Kawakami K, Kumamoto T, et al. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2007;30(7):519-21
   Web of Science ®Google Scholar
• Berciano J, Gallardo E, Garcia A, et al. Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family. J Neurol 2010;257(10):1633-41
   PubMed Web of Science ®Google Scholar